Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEB-01 in Pediatric Patients With Locally Resectable Abdominal Tumors
NCT06986811Phase 2Active, not recruiting
- Sponsor
- Cebiotex
- Start
- May 2025
- Primary completion
- May 2029
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CEB-01 in abdominal mass, soft tissue sarcoma (STS), neuroblastoma and 6 more (2 arms), sponsored by Cebiotex. Primary endpoint: Frequency of Adverse Events at 3 years. Started May 2025; status: active, not recruiting.
02
Drugs
CEB-01
03
Conditions
abdominal masssoft tissue sarcoma (STS)neuroblastomaWilms' tumorgerm cell tumor (GCT)
Beyond the preview
Go deeper on NCT06986811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986811.